EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation

Sehhoon Park; Bo Mi Ku; Hyun Ae Jung; Jong Mu Sun; Jin Seok Ahn; Se Hoon Lee; Keunchil Park; Myung Ju Ahn

doi:10.4143/crt.2020.278

EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation

Sehhoon Park
, Bo Mi Ku
, Hyun Ae Jung
, Jong Mu Sun
, Jin Seok Ahn
, Se Hoon Lee
, Keunchil Park
, Myung Ju Ahn

Division of Hematology-Oncology

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

Original language	English
Pages (from-to)	1288-1290
Number of pages	3
Journal	Cancer Research and Treatment
Volume	52
Issue number	4
DOIs	https://doi.org/10.4143/crt.2020.278
State	Published - Oct 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

ErbB receptors
Lazertinib
Non-small cell lung cancer
Third-generation EGFR tyrosine kinase inhibitor

Access to Document

10.4143/crt.2020.278

Cite this

@article{487f746aac8d4fb6a56c996d50470e61,

title = "EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation",

abstract = "The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.",

keywords = "ErbB receptors, Lazertinib, Non-small cell lung cancer, Third-generation EGFR tyrosine kinase inhibitor",

author = "Sehhoon Park and Ku, \{Bo Mi\} and Jung, \{Hyun Ae\} and Sun, \{Jong Mu\} and Ahn, \{Jin Seok\} and Lee, \{Se Hoon\} and Keunchil Park and Ahn, \{Myung Ju\}",

note = "Publisher Copyright: {\textcopyright} 2020 by the Korean Cancer Association.",

year = "2020",

month = oct,

doi = "10.4143/crt.2020.278",

language = "English",

volume = "52",

pages = "1288--1290",

journal = "Cancer Research and Treatment",

issn = "1598-2998",

publisher = "Korean Cancer Association",

number = "4",

}

TY - JOUR

T1 - EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation

AU - Park, Sehhoon

AU - Ku, Bo Mi

AU - Jung, Hyun Ae

AU - Sun, Jong Mu

AU - Ahn, Jin Seok

AU - Lee, Se Hoon

AU - Park, Keunchil

AU - Ahn, Myung Ju

PY - 2020/10

Y1 - 2020/10

N2 - The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

AB - The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI, lazertinib, which showed promising clinical efficacy in phase 1-2 study. The patients showed resistance to the treatment by acquiring the additional EGFR C797S mutation in cis which is also confirmed from the patient-derived cell lines.

KW - ErbB receptors

KW - Lazertinib

KW - Non-small cell lung cancer

KW - Third-generation EGFR tyrosine kinase inhibitor

UR - https://www.scopus.com/pages/publications/85093901575

U2 - 10.4143/crt.2020.278

DO - 10.4143/crt.2020.278

M3 - Article

C2 - 32599977

AN - SCOPUS:85093901575

SN - 1598-2998

VL - 52

SP - 1288

EP - 1290

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

IS - 4

ER -

EGFR C797S as a resistance mechanism of lazertinib in non-small cell lung cancer with EGFR T790M mutation

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this